Trial Profile

A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects With Solid Tumours.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Oct 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Rosiglitazone
Indications Renal cancer; Solid tumours; Thyroid cancer
Focus Pharmacokinetics; Registrational

Most Recent Events

18 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
02 Jun 2012 Interim results from a cohort of renal cell carcinoma patients have been presented at ASCO-2012 according to an Exelixis media release. Results were also summarised in the media release.
24 May 2012 Planned end date changed from 1 Dec 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com